Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results (January 2025) showed a 62% gastrointestinal overall response rate at Day 28 and 1-year ...

Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...

The EUR/JPY cross may find initial support at the nine-day EMA of 161.79, followed by the ascending channel’s lower boundary ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials to keep an eye on in 2025.

The EU pharma legislation wants to turn paper leaflets in medication packaging into QR codes — driven by Big Pharma influence — but patients argue this change creates unnecess ...

The natural gas market has initially tried to rally again on Wednesday, but at the $4 level, we continue to see a lot of resistance. At this point in time, the market is starting to focus on a lack of ...

The integration of AI and cloud technologies is transforming pharmaceutical manufacturing regulations, focusing on safety, efficiency, and global harmonization.

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatmen ...

The crude oil markets continue to see a lot of buying, as it looks like we are starting to price in more European demand, as ...

The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its ...